Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

Epilepsia

Volumn 50, Issue 3, 2009, Pages 443-453

  Halász, Péter ^a,b   Kälviäinen, Reetta ^c   Mazurkiewicz Beldzińska, Maria ^d   Rosenow, Felix ^e   Doty, Pamela ^f   Hebert, David ^f   Sullivan, Timothy ^f  

^a National Institute of Psychiatry and Neurology ^*

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c Kuopio University Hospital   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drugs; Epilepsy; Lacosamide; Partial onset seizures; Randomized controlled trial

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; TREATMENT RESPONSE; VERTIGO; VOMITING;

EID: 61849088333     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2008.01951.x     Document Type: Article

References (30)

1. Andurkar SV, Stables JP, Kohn H 1999) The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 7 : 2381 2389.
2. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD 2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48 : 1308 1317.
3. Beyreuther B, Callizot N, Stöhr T 2006) Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 539 : 64 70.
4. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T 2007) Lacosamide: a review of preclinical properties. CNS Drug Reviews 13 : 21 42.
5. Bialer M 2002) New antiepileptic drugs currently in clinical trials: is there a strategy in their development? Ther Drug Monit 24 : 85 90.
6. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E 2002) Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51 : 31 71.
7. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T 2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73 : 1 52.
8. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd G 2008) Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49 : 418 424.
9. Brandt C, Heile A, Potschka H, Stoehr T, Loscher W 2006) Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47 : 1803 1809.
10. Brodie MJ, Kwan P 2002) Staged approach to epilepsy management. Neurology 58 (Suppl 5 S2 S8.
11. Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R 2004) Food does not affect the pharmacokinetics of SPM 927 (Abstract 2.342). Epilepsia 45 (Suppl 7 307.
12. Cramer JA, Ben-Menachem E, French J 2001) Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 47 : 17 25.
13. Doty P, Rudd GD, Stoehr T, Thomas D 2007) Lacosamide. Neurotherapeutics 4 : 145 148.
14. Errington AC, Coyne L, Stöhr T, Selve N, Lee G 2006) Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50 : 1016 1029.
15. Errington AC, Stöhr T, Heers C, Lees G 2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73 : 157 169.
16. Horstmann R, Bonn R, Cawello W, Doty P, Rudd D 2002) Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927 (Abstract 2.174). Epilepsia 43 (Suppl 7 188.
17. Horstmann R, Bonn R, Cawello W, Doty P, Rudd D 2003) SPM 927 does not interact with valproic acid and carbamazepine (Abstract 1.271). Epilepsia 44 (Suppl 9 97.
18. Hovinga CA 2003) SPM-927 (Schwarz Pharma). IDrugs 6 : 479 485.
19. ILAE 1981) Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22 : 489 501.
20. Krauss G, Vaiciene N, Ben-Menachem E, Johnson M, Mameniskiene R, Brock M 2007) Intravenous lacosamide as replacement for oral Lacosamide in subjects with partial seizures: a multicenter, open-label, inpatient trial examining safety and tolerability of 10- and 15-minute infusion durations. Presented at the 61st Annual American Epilepsy Society Meeting, Philadelphia, PA, November 30-December 4, 2007.
21. Kropeit D, Scharfenecker U, Schiltmeyer B, Koch B, Rudd GD, Cawello W, Horstmann R 2006) Lacosamide has low potential for drug-drug interaction (Abstract 851). J Pain 7 : S63.
22. Kwan P, Brodie MJ 2000) Early identification of refractory epilepsy. N Engl J Med 342 : 314 319.
23. Marson AG, Kadir ZA, Chadwick DW 1996) New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 313 : 1169 1174.
24. Marson AG, Kadir ZA, Hutton JL, Chadwick DW 1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38 : 859 880.
25. Sander JW 1998) New drugs for epilepsy. Curr Opin Neurol 11 : 141 148.
26. Sander JW, Bell GS 2004) Reducing mortality: an important aim of epilepsy management. J Neurol Neurosurg Psychiatry 75 : 349 351.
27. Sheets PL, Heers C, Stoehr T, Cummins TR 2008) Differential block of sensory neuronal voltage-gated sodium channels by lacosamide, lidocaine and carbamazepine. J Pharmacol Exp Ther 326 : 89 99.
28. Shneker BF, Fountain NB 2003) Epilepsy. Dis Mon 49 : 426 478.
29. Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS 2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74 : 147 154.
30. Thomas D, Horstmann R, Scharfenecker U, Yates S, Nickel B, Doty P 2007) Lacosamide has low potential for drug-drug-interaction. Poster presented at: The American Society of Consultant Pharmacists 38th Annual Meeting, Philadelphia, PA, November 14-17, 2007.